Biolase Technology, Inc. (BIOL) Posts Q1 Loss of 11c/Share

Biolase Technology, Inc. (NASDAQ: BIOL) reported Q1 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $11.5 million versus the consensus estimate of $13.29 million.

For earnings history and earnings-related data on Biolase Technology, Inc. (BIOL) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Western Digital (WDC) Tops Q3 EPS by 42c; offers guidance
• Robert Half International (RHI) Reports In-Line Q1 EPS